Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C

Juanjie Tang; Tanya Novak; Julian Hecker; Gabrielle Grubbs; Fatema Tuz Zahra; Lorenza Bellusci; Sara Pourhashemi; Janet Chou; Kristin Moffitt; Natasha B. Halasa; Stephanie P. Schwartz; Tracie C. Walker; Keiko M. Tarquinio; Matt S. Zinter; Mary A. Staat; Shira J. Gertz; Natalie Z. Cvijanovich; Jennifer E. Schuster; Laura L. Loftis; Bria M. Coates; Elizabeth H. Mack; Katherine Irby; Julie C. Fitzgerald; Courtney M. Rowan; Michele Kong; Heidi R. Flori; Aline B. Maddux; Steven L. Shein; Hillary Crandall; Janet R. Hume; Charlotte V. Hobbs; Adriana H. Tremoulet; Chisato Shimizu; Jane C. Burns; Sabrina R. Chen; Hye Kyung Moon; Christoph Lange; Adrienne G. Randolph; Surender Khurana

doi:10.1038/s41467-022-30649-1

Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C

Juanjie Tang
, Tanya Novak
, Julian Hecker
, Gabrielle Grubbs
, Fatema Tuz Zahra
, Lorenza Bellusci
, Sara Pourhashemi
, Janet Chou
, Kristin Moffitt
, Natasha B. Halasa
, Stephanie P. Schwartz
, Tracie C. Walker
, Keiko M. Tarquinio
, Matt S. Zinter
, Mary A. Staat
, Shira J. Gertz
, Natalie Z. Cvijanovich
, Jennifer E. Schuster
, Laura L. Loftis
, Bria M. Coates

Elizabeth H. Mack, Katherine Irby, Julie C. Fitzgerald, Courtney M. Rowan, Michele Kong, Heidi R. Flori, Aline B. Maddux, Steven L. Shein, Hillary Crandall, Janet R. Hume, Charlotte V. Hobbs, Adriana H. Tremoulet, Chisato Shimizu, Jane C. Burns, Sabrina R. Chen, Hye Kyung Moon, Christoph Lange, Adrienne G. Randolph, Surender Khurana

United States Food and Drug Administration
Boston Children's Hospital
Harvard University
Brigham and Women's Hospital
Vanderbilt University
University of North Carolina at Chapel Hill
Emory University
University of California at San Francisco
University of Cincinnati
Cooperman Barnabas Medical Center
UCSF Benioff Children's Hospital Oakland
Children's Mercy Hospitals and Clinics
Baylor College of Medicine
Northwestern University
Medical University of South Carolina
University of Arkansas for Medical Sciences
University of Pennsylvania
Indiana University Bloomington
Division of Pediatric Critical Care
University of Michigan, Ann Arbor
University of Colorado Anschutz Medical Campus
Case Western Reserve University
University of Utah
University of Minnesota Twin Cities
University of Mississippi
Rady Children's Hospital

Producción científica › revisión exhaustiva

40 Citas (Scopus)

Resumen

Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by age-stratified analyses (<5, 5–11, 12–21 years) in 177 pediatric patients hospitalized with severe acute COVID-19, acute MIS-C, and in convalescent samples of outpatients with mild COVID-19 during 2020 and early 2021. Across all patients, less than 10% show neutralizing antibody titers against Omicron. Children <5 years of age hospitalized with severe acute COVID-19 have lower neutralizing antibodies to SARS-CoV-2 variants compared with patients >5 years of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These findings can influence transmission, re-infection and the clinical disease outcome from emerging SARS-CoV-2 variants and supports the need for vaccination in children.

Idioma original	English
Número de artículo	2979
Publicación	Nature Communications
Volumen	13
N.º	1
DOI	https://doi.org/10.1038/s41467-022-30649-1
Estado	Published - dic 2022
Publicado de forma externa	Sí

Acceder al documento

10.1038/s41467-022-30649-1

Otros archivos y enlaces

https://www.scopus.com/pages/publications/85130846753

Citar esto

Tang, J., Novak, T., Hecker, J., Grubbs, G., Zahra, F. T., Bellusci, L., Pourhashemi, S., Chou, J., Moffitt, K., Halasa, N. B., Schwartz, S. P., Walker, T. C., Tarquinio, K. M., Zinter, M. S., Staat, M. A., Gertz, S. J., Cvijanovich, N. Z., Schuster, J. E., Loftis, L. L., ... Khurana, S. (2022). Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nature Communications, 13(1), Artículo 2979. https://doi.org/10.1038/s41467-022-30649-1

@article{53c86be54dfd446abce362733f9f9584,

title = "Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C",

abstract = "Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by age-stratified analyses (<5, 5{\textendash}11, 12{\textendash}21 years) in 177 pediatric patients hospitalized with severe acute COVID-19, acute MIS-C, and in convalescent samples of outpatients with mild COVID-19 during 2020 and early 2021. Across all patients, less than 10\% show neutralizing antibody titers against Omicron. Children <5 years of age hospitalized with severe acute COVID-19 have lower neutralizing antibodies to SARS-CoV-2 variants compared with patients >5 years of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These findings can influence transmission, re-infection and the clinical disease outcome from emerging SARS-CoV-2 variants and supports the need for vaccination in children.",

author = "Juanjie Tang and Tanya Novak and Julian Hecker and Gabrielle Grubbs and Zahra, \{Fatema Tuz\} and Lorenza Bellusci and Sara Pourhashemi and Janet Chou and Kristin Moffitt and Halasa, \{Natasha B.\} and Schwartz, \{Stephanie P.\} and Walker, \{Tracie C.\} and Tarquinio, \{Keiko M.\} and Zinter, \{Matt S.\} and Staat, \{Mary A.\} and Gertz, \{Shira J.\} and Cvijanovich, \{Natalie Z.\} and Schuster, \{Jennifer E.\} and Loftis, \{Laura L.\} and Coates, \{Bria M.\} and Mack, \{Elizabeth H.\} and Katherine Irby and Fitzgerald, \{Julie C.\} and Rowan, \{Courtney M.\} and Michele Kong and Flori, \{Heidi R.\} and Maddux, \{Aline B.\} and Shein, \{Steven L.\} and Hillary Crandall and Hume, \{Janet R.\} and Hobbs, \{Charlotte V.\} and Tremoulet, \{Adriana H.\} and Chisato Shimizu and Burns, \{Jane C.\} and Chen, \{Sabrina R.\} and Moon, \{Hye Kyung\} and Christoph Lange and Randolph, \{Adrienne G.\} and Surender Khurana",

note = "Publisher Copyright: {\textcopyright} 2022, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.",

year = "2022",

month = dec,

doi = "10.1038/s41467-022-30649-1",

language = "English",

volume = "13",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

Tang, J, Novak, T, Hecker, J, Grubbs, G, Zahra, FT, Bellusci, L, Pourhashemi, S, Chou, J, Moffitt, K, Halasa, NB, Schwartz, SP, Walker, TC, Tarquinio, KM, Zinter, MS, Staat, MA, Gertz, SJ, Cvijanovich, NZ, Schuster, JE, Loftis, LL, Coates, BM, Mack, EH, Irby, K, Fitzgerald, JC, Rowan, CM, Kong, M, Flori, HR, Maddux, AB, Shein, SL, Crandall, H, Hume, JR, Hobbs, CV, Tremoulet, AH, Shimizu, C, Burns, JC, Chen, SR, Moon, HK, Lange, C, Randolph, AG & Khurana, S 2022, 'Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C', Nature Communications, vol. 13, n.º 1, 2979. https://doi.org/10.1038/s41467-022-30649-1

TY - JOUR

T1 - Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C

AU - Tang, Juanjie

AU - Novak, Tanya

AU - Hecker, Julian

AU - Grubbs, Gabrielle

AU - Zahra, Fatema Tuz

AU - Bellusci, Lorenza

AU - Pourhashemi, Sara

AU - Chou, Janet

AU - Moffitt, Kristin

AU - Halasa, Natasha B.

AU - Schwartz, Stephanie P.

AU - Walker, Tracie C.

AU - Tarquinio, Keiko M.

AU - Zinter, Matt S.

AU - Staat, Mary A.

AU - Gertz, Shira J.

AU - Cvijanovich, Natalie Z.

AU - Schuster, Jennifer E.

AU - Loftis, Laura L.

AU - Coates, Bria M.

AU - Mack, Elizabeth H.

AU - Irby, Katherine

AU - Fitzgerald, Julie C.

AU - Rowan, Courtney M.

AU - Kong, Michele

AU - Flori, Heidi R.

AU - Maddux, Aline B.

AU - Shein, Steven L.

AU - Crandall, Hillary

AU - Hume, Janet R.

AU - Hobbs, Charlotte V.

AU - Tremoulet, Adriana H.

AU - Shimizu, Chisato

AU - Burns, Jane C.

AU - Chen, Sabrina R.

AU - Moon, Hye Kyung

AU - Lange, Christoph

AU - Randolph, Adrienne G.

AU - Khurana, Surender

PY - 2022/12

Y1 - 2022/12

N2 - Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by age-stratified analyses (<5, 5–11, 12–21 years) in 177 pediatric patients hospitalized with severe acute COVID-19, acute MIS-C, and in convalescent samples of outpatients with mild COVID-19 during 2020 and early 2021. Across all patients, less than 10% show neutralizing antibody titers against Omicron. Children <5 years of age hospitalized with severe acute COVID-19 have lower neutralizing antibodies to SARS-CoV-2 variants compared with patients >5 years of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These findings can influence transmission, re-infection and the clinical disease outcome from emerging SARS-CoV-2 variants and supports the need for vaccination in children.

AB - Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by age-stratified analyses (<5, 5–11, 12–21 years) in 177 pediatric patients hospitalized with severe acute COVID-19, acute MIS-C, and in convalescent samples of outpatients with mild COVID-19 during 2020 and early 2021. Across all patients, less than 10% show neutralizing antibody titers against Omicron. Children <5 years of age hospitalized with severe acute COVID-19 have lower neutralizing antibodies to SARS-CoV-2 variants compared with patients >5 years of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These findings can influence transmission, re-infection and the clinical disease outcome from emerging SARS-CoV-2 variants and supports the need for vaccination in children.

UR - https://www.scopus.com/pages/publications/85130846753

U2 - 10.1038/s41467-022-30649-1

DO - 10.1038/s41467-022-30649-1

M3 - Article

C2 - 35624101

AN - SCOPUS:85130846753

SN - 2041-1723

VL - 13

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 2979

ER -

Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C

Resumen

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto